For people with antiphospholipid syndrome, how does rivaroxaban compare with standard dose warfarin for secondary prevention of thromboembolic events?

2020 ◽  
Author(s):  
Jane Burch ◽  
Sera Tort
Keyword(s):  
Secondary Prevention ◽  
Antiphospholipid Syndrome ◽  
Standard Dose ◽  
Thromboembolic Events ◽  
Dose Warfarin ◽  
Prevention Of Thromboembolic Events

scholarly journals Antiplatelet and Anticoagulant Agents for Secondary Prevention of Thromboembolic Events in People With Antiphospholipid Syndrome

Stroke ◽  
2018 ◽  
Vol 49 (3) ◽  
Author(s):  
Malgorzata M. Bala ◽  
Magdalena Celinska-Lowenhoff ◽  
Wojciech Szot ◽  
Agnieszka Padjas ◽  
Mateusz Kaczmarczyk ◽  
...  
Keyword(s):  
Secondary Prevention ◽  
Antiphospholipid Syndrome ◽  
Thromboembolic Events ◽  
Anticoagulant Agents ◽  
Prevention Of Thromboembolic Events

scholarly journals Direct oral anticoagulants versus vitamin K antagonists in patients with antiphospholipid syndrome: systematic review and meta-analysis

RMD Open ◽  
2021 ◽  
Vol 7 (2) ◽  
pp. e001678
Author(s):  
Nazariy Koval ◽  
Mariana Alves ◽  
Rui Plácido ◽  
Ana G Almeida ◽  
João Eurico Fonseca ◽  
...  
Keyword(s):  
Systematic Review ◽  
Antiphospholipid Syndrome ◽  
Vitamin K ◽  
Major Bleeding ◽  
Vitamin K Antagonists ◽  
Oral Anticoagulants ◽  
Direct Oral Anticoagulants ◽  
Thromboembolic Events ◽  
Bleeding Events ◽  
Prevention Of Thromboembolic Events

BackgroundDespite vitamin K antagonists (VKA) being the gold standard in the prevention of thromboembolic events in antiphospholipid syndrome (APS), non-vitamin K antagonists oral anticoagulants/direct oral anticoagulants (DOACs) have been used off-label.ObjectiveWe aimed to perform a systematic review comparing DOACs to VKA regarding prevention of thromboembolic events, occurrence of bleeding events and mortality in patients with APS.MethodsAn electronic database search was performed through MEDLINE, CENTRAL and Web of Science. After data extraction, we pooled the results using risk ratio (RR) and 95% CI. Heterogeneity was assessed using the I². The outcomes considered were all thromboembolic events as primary, and major bleeding, all bleeding events and mortality as secondary. Evidence confidence was assessed using the Grading of Recommendations Assessment, Development and Evaluation methodology.ResultsWe included 7 studies and a total of 835 patients for analyses. Thromboembolic events were significantly increased in DOACs arm, compared with VKA—RR 1.69, 95% CI 1.09 to 2.62, I²—24%, n=719, 6 studies. In studies using exclusively rivaroxaban, which was the most representative drug in all included studies, the thromboembolic risk was increased threefold (RR 3.36, 95% CI 1.53 to 7.37). The risks of major bleeding, all bleeding events and mortality were not significantly different from control arm. The grade of certainty of our results is very low.ConclusionsCurrent evidence suggests DOACs use, particularly rivaroxaban, among patients with APS, is less effective than VKA since it is associated with 69% increased risk of thromboembolic events.Trial registration numberCRD42020216178.

scholarly journals Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome

2017 ◽  
Author(s):  
Malgorzata M Bala ◽  
Magdalena Celinska-Lowenhoff ◽  
Wojciech Szot ◽  
Agnieszka Padjas ◽  
Mateusz Kaczmarczyk ◽  
...  
Keyword(s):  
Secondary Prevention ◽  
Antiphospholipid Syndrome ◽  
Thromboembolic Events ◽  
Anticoagulant Agents

scholarly journals Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome

2020 ◽  
Author(s):  
Malgorzata M Bala ◽  
Magdalena Celinska-Lowenhoff ◽  
Wojciech Szot ◽  
Agnieszka Padjas ◽  
Mateusz Kaczmarczyk ◽  
...  
Keyword(s):  
Secondary Prevention ◽  
Antiphospholipid Syndrome ◽  
Thromboembolic Events ◽  
Anticoagulant Agents

scholarly journals Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome

2016 ◽  
Author(s):  
Malgorzata M Bala ◽  
Magdalena Celinska-Lowenhoff ◽  
Agnieszka Padjas ◽  
Wojciech Szot ◽  
Anetta Undas
Keyword(s):  
Secondary Prevention ◽  
Antiphospholipid Syndrome ◽  
Thromboembolic Events ◽  
Anticoagulant Agents

Prevention of Thromboembolic Events in Atrial Fibrillation

1997 ◽  
Vol 78 (01) ◽  
pp. 377-381 ◽  
Author(s):  
Birgitte Gade Koefoed ◽  
Annette Lemche Gulløv ◽  
Palle Petersen
Keyword(s):  
Atrial Fibrillation ◽  
Thromboembolic Events ◽  
Prevention Of Thromboembolic Events

C0473: Prevention of Thromboembolic Events? European Registry in Venous Thromboembolism - Design of the Prefer in VTE

2014 ◽  
Vol 133 ◽  
pp. S122
Author(s):  
A. Cohen ◽  
R. Bauersachs ◽  
A. Gitt ◽  
P. Laeis ◽  
P. Mismetti ◽  
...  
Keyword(s):  
Venous Thromboembolism ◽  
Thromboembolic Events ◽  
Prevention Of Thromboembolic Events ◽  
European Registry
Sign in / Sign up

Export Citation Format

Share Document